Parker Institute for Cancer Immunotherapy shared a post on LinkedIn:
“A new study highlights progress toward one of the field’s most ambitious goals in cell therapy: in vivo CAR-T. Azalea Therapeutics, a PICI connected company, published a report in Nature Magazine proving that its approach can generate CAR-T cells directly in the body and clear both blood and solid tumors in mice.
By using a precise, multi-step gene editing system, the team was able to target the right cells and the right location in the genome, addressing one of the biggest safety challenges in the field.
If successful in humans, this approach could simplify manufacturing, expand access, and unlock broader use of CAR-T therapies.
Read more here.”
Other articles from Parker Institute for Cancer Immunotherapy.